Clinical Research, Pharma & Healthcare FinancingUpdate on Phase 3 Study of E. coli Vaccine CandidateGlobeNewswireFebruary 13, 2025February 14, 2025 by GlobeNewswireFebruary 13, 2025February 14, 2025037 Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted...
